EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

1‐Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance

Isabella Supardi Parida iD, Soo Takasu iD, Junya Ito iD, Takahiro Eitsuka iD, Kiyotaka Nakagawa iD

The FASEB Journal · 2024

DOI: 10.1096/fj.202302600r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Isabella Supardi Parida und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Food Function Analysis, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan. Hauptthemen laut MEDLINE: Alzheimer Disease, Insulin Resistance, 1-Deoxynojirimycin, Neurons. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin resistance, the hallmark of type 2 diabetes mellitus (T2DM), has emerged as a pathological feature in Alzheimer's disease (AD). Given the shared role of insulin resistance in T2DM and AD, repurposing peripheral insulin sensitizers is a promising strategy to preserve neuronal insulin sensitivity and prevent AD. 1‐Deoxynojirimycin (DNJ), a bioactive iminosugar, exhibited insulin‐sensitizing effects in metabolic tissues and was detected in brain tissue post‐oral intake. However, its impact on brain and neuronal insulin signaling has not been described. Here, we investigated the effect of DNJ treatment on insulin signaling and AD markers in insulin‐resistant human SK‐N‐SH neuroblastoma, a cellular model of neuronal insulin resistance. Our findings show that DNJ increased the expression of insulin signaling genes and the phosphorylation status of key molecules implicated in insulin resistance (Y1146‐pIRβ, S473‐pAKT, S9‐GSK3B) while also elevating the expression of glucose transporters Glut3 and Glut4 , resulting in higher glucose uptake upon insulin stimuli. DNJ appeared to mitigate the insulin resistance‐driven increase in phosphorylated tau and Aβ 1‐42 levels by promoting insulin‐induced phosphorylation of GSK3B (a major tau kinase) and enhancing mRNA expression of the insulin‐degrading enzyme (IDE) pivotal for insulin and Aβ clearance. Overall, our study unveils probable mechanisms underlying the potential benefits of DNJ for AD, wherein DNJ attenuates tau and amyloid pathologies by reversing neuronal insulin resistance. This provides a scientific basis for expanding the use of DNJ‐containing products for neuroprotective purposes and prompts further research into compounds with similar mechanisms of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseInsulin Resistance1-DeoxynojirimycinNeuronsHumansCell Line, TumorAmyloid beta-Peptidestau ProteinsGlucose Transporter Type 3InsulinSignal TransductionGlucose Transporter Type 4Glycogen Synthase Kinase 3 betaPhosphorylationBiomarkers

Stichwörter der Autor:innen

1‐deoxynojirimycinAlzheimer's diseaseamyloidinsulin‐degrading enzymeneuronal insulin signalingtau

Substanzen

1-DeoxynojirimycinAmyloid beta-Peptidestau ProteinsGlucose Transporter Type 3InsulinGlucose Transporter Type 4Glycogen Synthase Kinase 3 betaSLC2A4 protein, humanBiomarkersSLC2A3 protein, human

Autor:innen und Institutionen

  • Laboratory of Food Function Analysis, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan.
  • Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • Laboratory of Pharmaceutical Analytical Chemistry, Gifu Pharmaceutical University, Gifu, Japan.

ORCID-Profile: Isabella Supardi Parida, Soo Takasu, Junya Ito, Takahiro Eitsuka, Kiyotaka Nakagawa

Förderung

  • MEXT | Japan Society for the Promotion of Science (JSPS)
  • Japan Society for the Promotion of Science

Zitieren

APA

Parida, I. S., Takasu, S., Ito, J., Eitsuka, T., & Nakagawa, K. (2024). 1‐Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance. The FASEB Journal. https://doi.org/10.1096/fj.202302600r

Vancouver

Parida IS, Takasu S, Ito J, Eitsuka T, Nakagawa K. 1‐Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance. The FASEB Journal. 2024. doi:10.1096/fj.202302600r

BibTeX
@article{Parida2024,
  author = {Parida, Isabella Supardi and Takasu, Soo and Ito, Junya and Eitsuka, Takahiro and Nakagawa, Kiyotaka},
  title = {1‐Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202302600r}
}
Kostenlos starten →